Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT02265744. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic lupus erythematosus in male and female adults. Patients who qualify will be randomized to either active BMS-931699 or placebo for initially, up to 24 weeks. Patients who complete the initial 24 weeks of treatment and who are responding to therapy will have the option to continue receiving BMS-931699 as part of a long-term extension (LTE). Disease activity and safety will be assessed over the course of the study through laboratory values, various rating scales accepted in systemic lupus erythematosus studies and patient self reporting.
Study identification
- NCT ID
- NCT02265744
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 730 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2014 (Actual)
- Primary completion
- Oct 26, 2017 (Actual)
- Completion
- Nov 30, 2017 (Actual)
- Last update posted
- Oct 7, 2019
2014 – 2017
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rheumatology Associates Of North Alabama, P.C. | Huntsville | Alabama | 35801 | — |
| St Jude Hospital Yorba Linda | Fullerton | California | 92835 | — |
| Valerius Med Group & Res Ctr Of Greater Long Beach, Inc. | Long Beach | California | 90806 | — |
| Harbor UCLA Medical Center | Torrance | California | 90509 | — |
| University Of Connecticut Health Center | Farmington | Connecticut | 06030 | — |
| Local Institution | Trumbull | Connecticut | 06611 | — |
| Center For Rheumatology, Immunology And Arthritis | Fort Lauderdale | Florida | 33309 | — |
| The Arthritis Center | Palm Harbor | Florida | 34684-3176 | — |
| Jefrey D. Lieberman, Md., Pc | Decatur | Georgia | 30033 | — |
| Coeur D'Alene Arthrit Clin | Coeur d'Alene | Idaho | 83814-2644 | — |
| Heartland Research Associates, Llc | Wichita | Kansas | 67207-5150 | — |
| Beth Israel Deaconess Med. Center Div. Of Gastroenterology | Boston | Massachusetts | 02215 | — |
| Physician Research Collaboration, Llc | Lincoln | Nebraska | 68516 | — |
| Albuquerque Clinical Trials | Albuquerque | New Mexico | 87102-2631 | — |
| North Shore Lij Health System | Great Neck | New York | 11021 | — |
| The Feinstein Institute For Medical Research | Manhasset | New York | 11030 | — |
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Joint and Muscle Medical Care and Research Institute (JMMCRI) | Charlotte | North Carolina | 28204 | — |
| Pmg Research Of Salisbury | Salisbury | North Carolina | 28144 | — |
| Oklahoma Medical Research Foundation | Oklahoma City | Oklahoma | 73104 | — |
| East Penn Rheumatology Associates, P.C. | Bethlehem | Pennsylvania | 18015 | — |
| Allegheny-Singer Research Institute (Asri) | Pittsburgh | Pennsylvania | 15224 | — |
| Tekton Research Inc | Austin | Texas | 78745 | — |
| Local Institution | Dallas | Texas | 75246 | — |
| Arthritis Northwest | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 96 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02265744, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 7, 2019 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02265744 live on ClinicalTrials.gov.